stockrowPROCEPT BioRobotics Corporation
PRCT Healthcare Medical Devices
PROCEPT BioRobotics Corporation’s revenue for fiscal 2025 (year ended December 2025) was $308.1 million, up 37.2% from fiscal 2024.
- Revenue
- +18.0%
- EPS
- −21.1%
- Free cash flow
- −1.57%
- Total debt
- +0.39%
Quarter to September 2026, against a year earlier
Follow PRCT
Alert me
PROCEPT BioRobotics Corporation (PRCT) EV/Sales
As of 5 November 2026, PROCEPT BioRobotics Corporation (PRCT) trades at a EV/Sales of 2.8×. Over the past ten years it has ranged from 0.0× (September 2021) to 41.4× (June 2022); the current reading is higher than 8% of that period. That is in line with the Medical Devices industry median of 2.7× and below the Healthcare sector median of 3.5×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 4.9× | (71.82%) |
| FY2024 | 17.4× | 35.45% |
| FY2023 | 12.9× | (39.19%) |
| FY2022 | 21.2× | 352.28% |
| FY2021 | 4.7× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Sep 2026 | 2.5× | (24.40%) |
| Jun 2026 | 3.3× | (12.90%) |
| Mar 2026 | 3.8× | (22.85%) |
| Dec 2025 | 4.9× | (15.66%) |
| 20 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| LMRI Lumexa Imaging Holdings, Inc. compare | 1.2× |
| ENOV Enovis Corporation compare | 1.3× |
| TNDM Tandem Diabetes Care, Inc. compare | 1.3× |
| IART Integra LifeSciences Holdings Corporation compare | 1.6× |
| ATEC Alphatec Holdings, Inc. compare | 2.0× |
| PRCT PROCEPT BioRobotics Corporation | 2.8× |
| AORT Artivion, Inc. compare | 3.2× |
| SIBN SiBone compare | 4.4× |
| IRMD iRadimed Corporation compare | 11.4× |
| Medical Devices industry median | 2.7× |
| Healthcare sector median | 3.5× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)